MORRISTOWN, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment...
Incumbent Board’s Claims of Progress Are Not Credible or Supported by DataAIM Maintains Relationship with CRO Co-Founded by a Convicted...
• PRT2527 demonstrated activity across a range of relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy • Prelude...
Milestone Surpasses All Previous Years Combined Production, Signifying Major Breakthrough in Commercialization EffortsANN ARBOR, Mich., Dec. 11, 2024 (GLOBE NEWSWIRE)...
Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was...
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused...
Former CEO of NPS Pharma brings strong biotech expertise to further accelerate GEn1E’s development and commercialization of dual signal modulators...
Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance Reallocates Resources to Metabolic...
TORONTO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a leading lifestyle and consumer packaged...
CDK2-directed MGD drove deep tumor regression in preclinical models of HR-positive/HER2-negative breast cancer when combined with either a CDK4/6 inhibitor...
BOSTON, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular...
VALENCIA, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming the production of radioisotopes, today announced it...
Positive topline data for CAN-2409 viral immunotherapy achieved primary endpoint by demonstrating statistically significant and clinically meaningful benefit when combined...
PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma...
US$452 million transaction at deemed price of US$3.20 per NewGen share Increased market capitalization and visibility will support NewGen’s continued...
ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stage Early clinical data are expected in...
Grant for "Personalized Medicine Enabled by Intelligent Sensing Systems” ProjectMUNICH, Dec. 11, 2024 (GLOBE NEWSWIRE) -- HMNC Brain Health, a...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated...
ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant...
U.S. total addressable market for five initial indications is $25 to $33 billion REMINDER: Business Update Conference Call begins at...